Bhatt DL, et al. - In this randomized, double-blind, placebo-controlled, phase 1 trial, researchers tested the premise that PB2452, a monoclonal antibody fragment that binds ticagrelor with high affinity, could be used to rapidly reverse the antiplatelet effects of ticagrelor (an oral P2Y₁₂ inhibitor), reducing the risk or severity of bleeding. Of the 64 randomized volunteers, 48 were assigned to receive PB2452 and 16 were assigned to receive placebo. According to findings, the administration of PB2452 in healthy volunteers provided immediate and sustained reversal of the antiplatelet effects of ticagrelor, as assessed by multiple assays. Adverse drug-related events were mainly issues having to do with the site of infusion.